Literature DB >> 28748418

Left ventricular function in patients with hypertrophic cardiomyopathy and its relation to myocardial fibrosis and exercise tolerance.

Dimitrios Maragiannis1, Paulino A Alvarez2, Mohamad G Ghosn2, Karen Chin2, Jeremy J Hinojosa2, John M Buergler2, Dipan J Shah2, Sherif F Nagueh3.   

Abstract

We sought to determine the relation between myocardial extracellular volume (ECV), left ventricular (LV) diastolic function, and exercise tolerance in patients with hypertrophic cardiomyopathy (HCM). Forty five HCM patients with an ejection fraction >50% and no previous septal reduction therapy underwent imaging by CMR and transthoracic echocardiography. CMR was used to quantify LV volumes, mass, EF, LA volumes, scar burden, pre and post contrast T1 relaxation times and ECV. Echocardiography was used to measure outflow tract gradients, mitral inflow and annular velocities, circumferential strain, systolic, early and late diastolic strain rates. Exercise duration and peak oxygen consumption were noted. HCM patients had increased native T1 relaxation time and ECV vs. controls [ECV controls: 24.7 (23.2-26.4) vs. HCM: 26.8 (24.6-31.3)%, P = 0.014]. Both parameters were significantly associated with LV diastolic dysfunction, circumferential strain, diastolic strain rate and peak oxygen consumption (r = -0.73, P < 0.001). Compared to controls, HCM patients have significantly longer native T1 relaxation time and higher ECV. These structural changes lead to worse LV global and segmental diastolic function and in turn reduced exercise tolerance.

Entities:  

Keywords:  Diastole; Fibrosis; Hypertrophic cardiomyopathy

Mesh:

Year:  2017        PMID: 28748418     DOI: 10.1007/s10554-017-1214-z

Source DB:  PubMed          Journal:  Int J Cardiovasc Imaging        ISSN: 1569-5794            Impact factor:   2.357


  42 in total

Review 1.  Standardized myocardial segmentation and nomenclature for tomographic imaging of the heart. A statement for healthcare professionals from the Cardiac Imaging Committee of the Council on Clinical Cardiology of the American Heart Association.

Authors:  Manuel D Cerqueira; Neil J Weissman; Vasken Dilsizian; Alice K Jacobs; Sanjiv Kaul; Waren K Laskey; Dudley J Pennell; John A Rumberger; Thomas Ryan; Mario S Verani
Journal:  Int J Cardiovasc Imaging       Date:  2002-02       Impact factor: 2.357

2.  Clinical profile and significance of delayed enhancement in hypertrophic cardiomyopathy.

Authors:  Martin S Maron; Evan Appelbaum; Caitlin J Harrigan; Jacki Buros; C Michael Gibson; Connie Hanna; John R Lesser; James E Udelson; Warren J Manning; Barry J Maron
Journal:  Circ Heart Fail       Date:  2008-06-23       Impact factor: 8.790

3.  Tissue Doppler imaging consistently detects myocardial contraction and relaxation abnormalities, irrespective of cardiac hypertrophy, in a transgenic rabbit model of human hypertrophic cardiomyopathy.

Authors:  S F Nagueh; H A Kopelen; D S Lim; W A Zoghbi; M A Quiñones; R Roberts; A J Marian
Journal:  Circulation       Date:  2000-09-19       Impact factor: 29.690

4.  Validation of sub-segmental visual scoring for the quantification of ischemic and nonischemic myocardial fibrosis using late gadolinium enhancement MRI.

Authors:  Nowell M Fine; Shruti Tandon; Han W Kim; Dipan J Shah; Terry Thompson; Maria Drangova; James A White
Journal:  J Magn Reson Imaging       Date:  2013-04-04       Impact factor: 4.813

5.  Myocardial scar visualized by cardiovascular magnetic resonance imaging predicts major adverse events in patients with hypertrophic cardiomyopathy.

Authors:  Oliver Bruder; Anja Wagner; Christoph J Jensen; Steffen Schneider; Peter Ong; Eva-Maria Kispert; Kai Nassenstein; Thomas Schlosser; Georg V Sabin; Udo Sechtem; Heiko Mahrholdt
Journal:  J Am Coll Cardiol       Date:  2010-06-25       Impact factor: 24.094

6.  A comprehensive evaluation of myocardial fibrosis in hypertrophic cardiomyopathy with cardiac magnetic resonance imaging: linking genotype with fibrotic phenotype.

Authors:  Andris H Ellims; Leah M Iles; Liang-han Ling; Belinda Chong; Ivan Macciocca; Glenn S Slavin; James L Hare; David M Kaye; Silvana F Marasco; Catriona A McLean; Paul A James; Desirée du Sart; Andrew J Taylor
Journal:  Eur Heart J Cardiovasc Imaging       Date:  2014-05-12       Impact factor: 6.875

7.  Prognostic value of quantitative contrast-enhanced cardiovascular magnetic resonance for the evaluation of sudden death risk in patients with hypertrophic cardiomyopathy.

Authors:  Raymond H Chan; Barry J Maron; Iacopo Olivotto; Michael J Pencina; Gabriele Egidy Assenza; Tammy Haas; John R Lesser; Christiane Gruner; Andrew M Crean; Harry Rakowski; James E Udelson; Ethan Rowin; Massimo Lombardi; Franco Cecchi; Benedetta Tomberli; Paolo Spirito; Francesco Formisano; Elena Biagini; Claudio Rapezzi; Carlo Nicola De Cecco; Camillo Autore; E Francis Cook; Susie N Hong; C Michael Gibson; Warren J Manning; Evan Appelbaum; Martin S Maron
Journal:  Circulation       Date:  2014-08-05       Impact factor: 29.690

8.  Association between regional ventricular function and myocardial fibrosis in hypertrophic cardiomyopathy assessed by speckle tracking echocardiography and delayed hyperenhancement magnetic resonance imaging.

Authors:  Zoran B Popović; Deborah H Kwon; Micky Mishra; Adisai Buakhamsri; Neil L Greenberg; Maran Thamilarasan; Scott D Flamm; James D Thomas; Harry M Lever; Milind Y Desai
Journal:  J Am Soc Echocardiogr       Date:  2008-12       Impact factor: 5.251

9.  Evaluation of diffuse myocardial fibrosis in heart failure with cardiac magnetic resonance contrast-enhanced T1 mapping.

Authors:  Leah Iles; Heinz Pfluger; Arintaya Phrommintikul; Joshi Cherayath; Pelin Aksit; Sandeep N Gupta; David M Kaye; Andrew J Taylor
Journal:  J Am Coll Cardiol       Date:  2008-11-04       Impact factor: 24.094

10.  Native T1 mapping in differentiation of normal myocardium from diffuse disease in hypertrophic and dilated cardiomyopathy.

Authors:  Valentina O Puntmann; Tobias Voigt; Zhong Chen; Manuel Mayr; Rashed Karim; Kawal Rhode; Ana Pastor; Gerald Carr-White; Reza Razavi; Tobias Schaeffter; Eike Nagel
Journal:  JACC Cardiovasc Imaging       Date:  2013-03-14
View more
  9 in total

Review 1.  Myocardial Interstitial Fibrosis in Nonischemic Heart Disease, Part 3/4: JACC Focus Seminar.

Authors:  Javier Díez; Arantxa González; Jason C Kovacic
Journal:  J Am Coll Cardiol       Date:  2020-05-05       Impact factor: 24.094

2.  Exercise Recommendations in Pediatric HCM: Variation and Influence of Provider Characteristics.

Authors:  Robert D Whitehill; Seshadri Balaji; Michael Kelleman; Stephanie F Chandler; Dominic J Abrams; Chad Mao; Peter Fischbach; Robert Campbell
Journal:  Pediatr Cardiol       Date:  2021-08-18       Impact factor: 1.655

Review 3.  Fibrosis in hypertrophic cardiomyopathy: role of novel echo techniques and multi-modality imaging assessment.

Authors:  Efstathios D Pagourelias; Georgios M Alexandridis; Vassilios P Vassilikos
Journal:  Heart Fail Rev       Date:  2021-05-15       Impact factor: 4.214

4.  Role of the Extracellular Matrix in the Pathogenesis of Hypertrophic Cardiomyopathy.

Authors:  Ali J Marian
Journal:  JACC Basic Transl Sci       Date:  2019-08-26

5.  Hemodynamic determinants of left atrial strain in patients with hypertrophic cardiomyopathy: A combined echocardiography and CMR study.

Authors:  Bhupendar Tayal; Maan Malahfji; John M Buergler; Dipan J Shah; Sherif F Nagueh
Journal:  PLoS One       Date:  2021-02-10       Impact factor: 3.240

6.  Associations of Social Vulnerability Index With Pathologic Myocardial Findings at Autopsy.

Authors:  Ashwin Sunderraj; Adovich Rivera; Meghna Gaddam; Sarah Kim; Juan McCook; Janelle O'Neal; Jon Lomasney; Donald M Lloyd-Jones; Yvonne Baumer; Tiffany M Powell-Wiley; Matthew J Feinstein
Journal:  Front Cardiovasc Med       Date:  2021-12-23

7.  Endogenous T1ρ cardiovascular magnetic resonance in hypertrophic cardiomyopathy.

Authors:  Elizabeth W Thompson; Srikant Kamesh Iyer; Michael P Solomon; Zhaohuan Li; Qiang Zhang; Stefan Piechnik; Konrad Werys; Sophia Swago; Brianna F Moon; Zachary B Rodgers; Anya Hall; Rishabh Kumar; Nosheen Reza; Jessica Kim; Alisha Jamil; Benoit Desjardins; Harold Litt; Anjali Owens; Walter R T Witschey; Yuchi Han
Journal:  J Cardiovasc Magn Reson       Date:  2021-10-25       Impact factor: 5.364

Review 8.  Treatment of myocardial interstitial fibrosis in pathological myocardial hypertrophy.

Authors:  Fuyu Zhu; Peng Li; Yanhui Sheng
Journal:  Front Pharmacol       Date:  2022-09-30       Impact factor: 5.988

9.  Examining the impact of inducible ischemia on myocardial fibrosis and exercise capacity in hypertrophic cardiomyopathy.

Authors:  Maan Malahfji; Alpana Senapati; Dany Debs; Clara Angulo; Yang Zhan; Sherif F Nagueh; Dipan J Shah
Journal:  Sci Rep       Date:  2020-09-29       Impact factor: 4.379

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.